vs

Side-by-side financial comparison of Mind Medicine (MindMed) Inc. (DFTX) and IM Cannabis Corp. (IMCC). Click either name above to swap in a different company.

Mind Medicine (MindMed) Inc. is the larger business by last-quarter revenue ($906.0K vs $10.1K, roughly 89.4× IM Cannabis Corp.). IM Cannabis Corp. runs the higher net margin — -7.8% vs -2634.0%, a 2626.2% gap on every dollar of revenue.

Definium Therapeutics, Inc., formerly known as MindMed, is a New York-based biotechnology company that is currently developing clinical and therapeutic applications for psychedelic and, more broadly, psychoplastogenic drugs.

IM Cannabis Corp is a global cannabis enterprise focused on the cultivation, production, distribution and retail of medical and adult-use cannabis products. It runs business across core markets including North America, the European Union and Israel, offering branded cannabis goods, wellness derivatives and related consumer products to medical patients and recreational users.

DFTX vs IMCC — Head-to-Head

Bigger by revenue
DFTX
DFTX
89.4× larger
DFTX
$906.0K
$10.1K
IMCC
Higher net margin
IMCC
IMCC
2626.2% more per $
IMCC
-7.8%
-2634.0%
DFTX

Income Statement — Q4 2023 vs Q3 2025

Metric
DFTX
DFTX
IMCC
IMCC
Revenue
$906.0K
$10.1K
Net Profit
$-23.9M
$-790
Gross Margin
22.7%
Operating Margin
-2450.8%
-6.9%
Net Margin
-2634.0%
-7.8%
Revenue YoY
-16.1%
Net Profit YoY
-386.7%
EPS (diluted)
$-0.58

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DFTX
DFTX
IMCC
IMCC
Q3 25
$10.1K
Q2 25
$8.8K
Q4 24
$11.8K
Q3 24
$9.0K
Q2 24
$10.8M
Q1 24
$9.1K
Q4 23
$906.0K
Q3 23
$1.2M
Net Profit
DFTX
DFTX
IMCC
IMCC
Q3 25
$-790
Q2 25
$-4.4K
Q4 24
Q3 24
$-1.6K
Q2 24
$-2.5M
Q1 24
Q4 23
$-23.9M
Q3 23
$-17.9M
Gross Margin
DFTX
DFTX
IMCC
IMCC
Q3 25
22.7%
Q2 25
14.7%
Q4 24
Q3 24
21.4%
Q2 24
5.7%
Q1 24
23.2%
Q4 23
Q3 23
Operating Margin
DFTX
DFTX
IMCC
IMCC
Q3 25
-6.9%
Q2 25
-46.7%
Q4 24
-236.7%
Q3 24
18.3%
Q2 24
-19.5%
Q1 24
28.9%
Q4 23
-2450.8%
Q3 23
-1858.6%
Net Margin
DFTX
DFTX
IMCC
IMCC
Q3 25
-7.8%
Q2 25
-49.9%
Q4 24
Q3 24
-17.3%
Q2 24
-23.4%
Q1 24
Q4 23
-2634.0%
Q3 23
-1541.1%
EPS (diluted)
DFTX
DFTX
IMCC
IMCC
Q3 25
Q2 25
Q4 24
Q3 24
Q2 24
Q1 24
Q4 23
$-0.58
Q3 23
$-0.45

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DFTX
DFTX
IMCC
IMCC
Cash + ST InvestmentsLiquidity on hand
$99.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$78.1M
Total Assets
$124.5M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DFTX
DFTX
IMCC
IMCC
Q3 25
Q2 25
Q4 24
$630.0K
Q3 24
Q2 24
$511.0K
Q1 24
Q4 23
$99.7M
Q3 23
$117.7M
Stockholders' Equity
DFTX
DFTX
IMCC
IMCC
Q3 25
Q2 25
Q4 24
$2.3M
Q3 24
Q2 24
$4.0M
Q1 24
Q4 23
$78.1M
Q3 23
$96.0M
Total Assets
DFTX
DFTX
IMCC
IMCC
Q3 25
Q2 25
Q4 24
$28.6M
Q3 24
Q2 24
$29.4M
Q1 24
Q4 23
$124.5M
Q3 23
$141.6M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DFTX
DFTX
IMCC
IMCC
Operating Cash FlowLast quarter
$-20.6M
$2.3K
Free Cash FlowOCF − Capex
$2.2K
FCF MarginFCF / Revenue
21.6%
Capex IntensityCapex / Revenue
0.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DFTX
DFTX
IMCC
IMCC
Q3 25
$2.3K
Q2 25
Q4 24
$-786.2K
Q3 24
Q2 24
Q1 24
$-4.4K
Q4 23
$-20.6M
Q3 23
$-16.6M
Free Cash Flow
DFTX
DFTX
IMCC
IMCC
Q3 25
$2.2K
Q2 25
Q4 24
Q3 24
Q2 24
Q1 24
$-4.7K
Q4 23
Q3 23
FCF Margin
DFTX
DFTX
IMCC
IMCC
Q3 25
21.6%
Q2 25
Q4 24
Q3 24
Q2 24
Q1 24
-51.7%
Q4 23
Q3 23
Capex Intensity
DFTX
DFTX
IMCC
IMCC
Q3 25
0.9%
Q2 25
Q4 24
Q3 24
Q2 24
Q1 24
3.3%
Q4 23
Q3 23

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons